Shin Nippon Biomedical Laboratories Balance Sheet Health
Financial Health criteria checks 3/6
Shin Nippon Biomedical Laboratories has a total shareholder equity of ¥33.4B and total debt of ¥33.3B, which brings its debt-to-equity ratio to 100%. Its total assets and total liabilities are ¥81.7B and ¥48.3B respectively. Shin Nippon Biomedical Laboratories's EBIT is ¥2.8B making its interest coverage ratio -58.9. It has cash and short-term investments of ¥11.1B.
Key information
100.0%
Debt to equity ratio
JP¥33.35b
Debt
| Interest coverage ratio | -58.9x |
| Cash | JP¥11.10b |
| Equity | JP¥33.36b |
| Total liabilities | JP¥48.31b |
| Total assets | JP¥81.66b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: YB3's short term assets (¥33.2B) exceed its short term liabilities (¥23.8B).
Long Term Liabilities: YB3's short term assets (¥33.2B) exceed its long term liabilities (¥24.5B).
Debt to Equity History and Analysis
Debt Level: YB3's net debt to equity ratio (66.7%) is considered high.
Reducing Debt: YB3's debt to equity ratio has increased from 61% to 100% over the past 5 years.
Debt Coverage: YB3's debt is not well covered by operating cash flow (6.3%).
Interest Coverage: YB3 earns more interest than it pays, so coverage of interest payments is not a concern.